Literature DB >> 7119475

Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy.

E DeStefano, R M Friedman, A E Friedman-Kien, J J Goedert, D Henriksen, O T Preble, J A Sonnabend, J Vilcek.   

Abstract

Some immunologic parameters in homosexual patients with Kaposi's sarcoma (KS) or unexplained lymphadenopathy resemble findings in patients with autoimmune diseases such as systemic lupus erythematosus (SLE). Many patients with SLE have an unusual acid-labile form of human leukocyte interferon (HuIFN-alpha) in their serum. Sera from 91 homosexual men were tested for the presence of HuIFN. Of 27 patients with KS, 17 had significant titers of HuIFN in their serum. Ten of 35 patients with lymphadenopathy and three of four patients with other clinical symptoms also had circulating HuIFN. In contrast, only two of 25 apparently healthy subjects had serum HuIFN. All 32 samples of HuIFN had antiviral activity on bovine cells, a characteristic of HuIFN-alpha, and all of 14 representative samples tested were neutralized by antibody to HuIFN-alpha. In addition, the HuIFN-alpha in six of eight representative patients was inactivated at pH 2 and therefore appears to be similar to the HuIFN-alpha found in patients with SLE. These findings suggest that an autoimmune disorder may underly lymphadenopathy and KS in homosexual men.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7119475     DOI: 10.1093/infdis/146.4.451

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  62 in total

Review 1.  HIV-1 immunopathogenesis in humanized mouse models.

Authors:  Liguo Zhang; Lishan Su
Journal:  Cell Mol Immunol       Date:  2012-04-16       Impact factor: 11.530

2.  Spontaneous release of interferon as a predictor of clinical evolution in HIV-positive subjects.

Authors:  A Biglino; A Surbone; F Lipani; N Cappello; B Forno; A M Pollono; M Busso; A Pugliese
Journal:  Infection       Date:  1991 Jan-Feb       Impact factor: 3.553

Review 3.  Type I interferon: understanding its role in HIV pathogenesis and therapy.

Authors:  Steven E Bosinger; Netanya S Utay
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

4.  Impaired monocyte-to-macrophage maturation in patients with lymphadenopathy syndrome.

Authors:  J Offenberger; T Lieu; O Frick; A J Ammann
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

5.  Serum alpha interferon and lymphocyte inclusions in systemic lupus erythematosus.

Authors:  J H Klippel; S Carette; O T Preble; R M Friedman; P M Grimley
Journal:  Ann Rheum Dis       Date:  1985-02       Impact factor: 19.103

6.  HIV-1 Env and Nef Cooperatively Contribute to Plasmacytoid Dendritic Cell Activation via CD4-Dependent Mechanisms.

Authors:  Natalia J Reszka-Blanco; Vijay Sivaraman; Liguo Zhang; Lishan Su
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

7.  Association of alpha interferon production with natural killer cell lysis of U937 cells infected with human immunodeficiency virus.

Authors:  G Rappocciolo; J F Toso; D J Torpey; P Gupta; C R Rinaldo
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

Review 8.  Current humanized mouse models for studying human immunology and HIV-1 immuno-pathogenesis.

Authors:  LiGuo Zhang; Eric Meissner; JianZhu Chen; LiShan Su
Journal:  Sci China Life Sci       Date:  2010-03-07       Impact factor: 6.038

9.  Induction of alpha interferon by human immunodeficiency virus type 1 in human monocyte-macrophage cultures.

Authors:  J Szebeni; C Dieffenbach; S M Wahl; C N Venkateshan; A Yeh; M Popovic; S Gartner; L M Wahl; M Peterfy; R M Friedman
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

10.  Selective decrease in human immunodeficiency virus type 1 (HIV-1)-induced alpha interferon production by peripheral blood mononuclear cells during HIV-1 infection.

Authors:  J Ferbas; J Navratil; A Logar; C Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.